Positive PD-L1 expression is associated with unfavorable clinical outcome in EGFR-mutated lung adenocarcinomas treated with EGFR-TKIs
J. Lee (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), B. Chang (Seoul, Republic of Korea), C. Choi (Seoul, Republic of Korea), Y. Kim (Seoul, Republic of Korea), H. Choi (Seoul, Republic of Korea), W. Kwak (Seoul, Republic of Korea), M. Park (Seoul, Republic of Korea), W. Jeon (Seoul, Republic of Korea)
Source: International Congress 2019 – Treatment of lung cancer
Session: Treatment of lung cancer
Session type: Poster Discussion
Number: 367
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Lee (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), B. Chang (Seoul, Republic of Korea), C. Choi (Seoul, Republic of Korea), Y. Kim (Seoul, Republic of Korea), H. Choi (Seoul, Republic of Korea), W. Kwak (Seoul, Republic of Korea), M. Park (Seoul, Republic of Korea), W. Jeon (Seoul, Republic of Korea). Positive PD-L1 expression is associated with unfavorable clinical outcome in EGFR-mutated lung adenocarcinomas treated with EGFR-TKIs. 367
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: